Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 301–400 of 943
Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases
Monastero, R., Camarda, C., Pipia, C., & Camarda, R. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.096420 · Cited by 44
Sugiyama, K., Aida, T., Nomura, M., Takayanagi, R., Zeilhofer, H. U., & Tanaka, K. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-17.2017 · Cited by 44
“Next, to investigate the role of NMDA receptors in spinal motor neuron death in GLAST / /GLT1cKO mice, we treated GLAST / /GLT1-cKO mice with memantine (Lipton, 2006), an NMDA receptor antagonist.”
MethodYang, J., Niu, Y., Simon, C., Seritan, A. L., Chen, L., Schneider, A., Moghaddam, S. T., Hagerman, P. J., Hagerman, R. J., & Olichney, J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.122 · Cited by 45
“Memantine, an uncompetitive antagonist of Nmethyl-D-aspartate (NMDA) glutamate receptor approved for the treatment of moderate-to-severe AD (Reisberg et al, 2003), has been suggested to be of therapeutic benefit in neurological disorders associated with overactivation of glutamate receptors, including Parkinson diseas…”
BackgroundResultInfluentialHu, S., Cui, W., Mak, S., Tang, J., Choi, C., Pang, Y., & Han, Y. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.022 · Cited by 44
Pervolaraki, E., Hall, S. P., Foresteire, D., Saito, T., Saido, T. C., Whittington, M. A., Lever, C., & Dachtler, J. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.040550 · Cited by 43
“NMDA dysfunction is well established in AD, such that one of the few drugs to ameliorate the symptoms of AD is the NMDA antagonist memantine (Lipton, 2006).”
Mechanistic Basis for Therapeutic Targeting of the Mitochondrial F1Fo-ATPase
Johnson, K. M., Cleary, J., Fierke, C. A., Opipari, A. W., & Glick, G. D. (2006) · ACS Chemical Biology · doi:10.1021/cb600143j · Cited by 44
Neuroprotection and neuroplasticity – A holistic approach and future perspectives
Muresanu, D. F. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.041 · Cited by 46
“It is well-known that NMDA activity upregulates hyperphosphorylation of tau protein [3].”
BackgroundInfluentialJiang, S. X., Zheng, R., Jin-qi, Z., Li, X.-L., Han, Z., & Hou, S. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.063 · Cited by 42
Filippi, L., Fiorini, P., Daniotti, M., Catarzi, S., Savelli, S., Fonda, C., Bartalena, L., Boldrini, A., Giampietri, M., Scaramuzzo, R. T., et al. (2012) · BMC Pediatrics · doi:10.1186/1471-2431-12-144 · Cited by 48
“These processes include the Ca overload in the mitochondria, responsible for the production of free radicals [6,11-13]; the activation of caspases and the release of factors inducing apoptosis [14-17]; the activation of a neuronal nitric oxide synthase (nNOS) that triggers the synthesis of nitric oxide (NO) and the fo…”
BackgroundCause or compensation?—Altered neuronal Ca2+ handling in Huntington's disease
Mackay, J. P., Nassrallah, W. B., & Raymond, L. A. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12817 · Cited by 45
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 43
“Similar to MK801, AP7 and 3-CPP have not been used in human trials due to fears of adverse side effects and potential toxicity [83,84].”
Zhang, C., Liu, X., Xu, H., Hu, G., Zhang, X., Xie, Z., Feng, D., Wu, R. X., Zhao, G., & Shi, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-64738-2 · Cited by 43
The role of NMDA receptors in the signal attenuation rat model of obsessive–compulsive disorder
Albelda, N., Bar-On, N., & Joel, D. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1808-9 · Cited by 44
“For example, both non-competitive NMDA antagonists and DCS were reported to worsen schizophrenia symptoms (Cascella et al. 1994; Lahti et al. 1995; Malhotra et al. 1997).”
BackgroundEfficacy of Memantine in Schizophrenic Patients: A Systematic Review
Iorio, G. D., Baroni, G., Lorusso, M., Montemitro, C., Spano, M. C., & Giannantonio, M. D. (2017) · Journal of Amino Acids · doi:10.1155/2017/7021071 · Cited by 43
“Glutamate-mediated excitotoxicity is due to an excessive stimulation of glutamate receptors even if extracellular glutamate levels are normal [12].”
BackgroundGonzález‐Cota, A. L., Martínez-Flores, D., Rosendo‐Pineda, M. J., & Vaca, L. A. (2024) · Cell Calcium · doi:10.1016/j.ceca.2024.102856 · Cited by 42
Annweiler, C., & Beauchet, O. (2012) · Drugs & Aging · doi:10.2165/11597550-000000000-00000 · Cited by 43
“The observed temporary benefits with memantine are believed to be mediated through its preferential binding to NMDA receptors that results in the inhibition of the prolonged influx of calcium ions.([28,29,32]) Consequently, there is a protection of the glutamatergic neurons by avoiding immediate neuronal necrosis thro…”
BackgroundFernández-Morales, J.-C., Arranz-Tagarro, J.-A., Calvo-Gallardo, E., Maroto, M., Padín, J.-F., & García, A. G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3001069 · Cited by 40
Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
Kikuchi, T. (2020) · Biomolecules · doi:10.3390/biom10081134 · Cited by 44
“, the faster unblocking kinetics) and interfering with subsequent normal synaptic transmission to provide efficacy while displaying minimal side effects [50,51,53,54].”
BackgroundMemantine selectively blocks extrasynaptic NMDA receptors in rat substantia nigra dopamine neurons
Wu, Y.-N., & Johnson, S. W. (2015) · Brain Research · doi:10.1016/j.brainres.2015.01.041 · Cited by 40
Stepanyan, T. D., Farook, J. M., Kowalski, A., Kaplan, E., Barron, S., & Littleton, J. M. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00801.x · Cited by 41
In vitro galantamine-memantine co-application: Mechanism of beneficial action
Zhao, X., Marszalec, W., Tóth, P. T., Huang, J. C., Yeh, J. Z., & Narahashi, T. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.007 · Cited by 40
Otto, R., Penzis, R., Gaube, F., Adolph, O., Föhr, K. J., Warncke, P., Robaa, D., Appenroth, D., Fleck, C., Enzensperger, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00958 · Cited by 39
Amyloid beta modulation of neuronal network activity in vitro
Charkhkar, H., Meyyappan, S., Matveeva, E. G., Moll, J. R., McHail, D. G., Peixoto, N., Cliff, R. O., & Pancrazio, J. J. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.036 · Cited by 45
“…rate with MB suggests the suppression of Aβ effects in the presence of MB. Application of 20 mM memantine to the cultures caused reduction in the activity by 48.172.2%, an effect mainly due to its role as an open-channel antagonist of the NMDA receptor (Lipton, 2006; Netzer and Bigalke, 1990).”
InfluentialThe Memantine Lombardy Study Group, Clerici, F., Vanacore, N., Elia, A., Alegiani, S. S., Pomati, S., Cas, R. D., Raschetti, R., & Mariani, C. B. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0618-0 · Cited by 41
“Memantine is a specific, moderate affinity, uncompetitive N-methyl-D-aspartate receptor antagonist, with rapid voltage-dependent kinetics [8].”
BackgroundPhencyclidine-Based New Psychoactive Substances
Wallach, J. V., & Brandt, S. D. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_124 · Cited by 42
Applications of Reactive Cysteine Profiling
Backus, K. M. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_120 · Cited by 43
Tronci, E., Fidalgo, C., Zianni, E., Collu, M., Stancampiano, R., Morelli, M., Gardoni, F., & Carta, M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.042 · Cited by 43
“Memantine, a derivative of amantadine, is a non-competitive NMDA receptor antagonist, which has been recently approved in Europe and USA for treatment of moderate to severe Alzheimer’s disease and other dementias (Witt et al., 2004; Lipton, 2006; Dominguez et al., 2011).”
BackgroundKotermanski, S. E., Johnson, J. W., & Thiels, E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.05.005 · Cited by 46
“However, there is substantial evidence favoring NMDARs as the principal site of action of both drugs (Lipton, 2006, Parsons et al., 2007, Rogawski and Wenk, 2003, Wenk et al., 2006).”
BackgroundHasel, P., Mckay, S., Qiu, J., & Hardingham, G. E. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.12.021 · Cited by 39
“Excitotoxicity is caused by the global or local accumulation of glutamate, leading to inappropriate activity of the NMDA subtype of glutamate receptor (NMDAR) which mediates Ca-dependent cell death and dysfunction [17,61].”
BackgroundN-Methyl-d-Aspartate Receptor Blockade Is Neuroprotective in Experimental Autoimmune Optic Neuritis
Sühs, K., Fairless, R., Williams, S. K., Heine, K., Cavalié, A., & Diem, R. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000073 · Cited by 40
“brain trauma and cerebral ischemia) is glutamatemediated excitotoxicity; both >-amino-3-hydroxy-5-methyl4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors have been implicated in these conditions (9).”
BackgroundKaranian, D. A., Baude, A. S., Brown, Q. B., Parsons, C. G., & Bahr, B. A. (2006) · Hippocampus · doi:10.1002/hipo.20214 · Cited by 38
“…of excitotoxic processes including ischemia, traumatic brain injury, and oxidative stress (see Kemp and MeKernan, 2002; Waxman and Lynch, 2005; Lipton, 2006), and perhaps contributes to Alzheimer's disease (AD) and other age-related disorders (Ulas et al., 1994; Hynd et al., 2004; Mishizen-…”
BackgroundAlhibshi, A., Odawara, A., & Suzuki, I. (2019) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.12.005 · Cited by 42
“Furthermore, Aβ1–42 may have the notable ability to enhance the mediated excitotoxicity of glutamate by specifically acting upon N-Methyl-D-aspartic acid (NMDA) receptors and thus, through an increased influx of Ca [49,50].”
BackgroundFinelli, M. J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00254 · Cited by 40
“To reduce NMDAR hyperactivity, the FDA-approved aminoadamantane compound, Memantine, an uncompetitive fast-off rate NMDAR antagonist that acts as an open-channel blocker was used initially (Chen et al., 1992; Chen and Lipton, 1997; Lipton, 2006).”
BackgroundMethodInfluentialLiu, W., Xu, Z., Deng, Y. L., Xu, B., Wei, Y., & Yang, T. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9386-3 · Cited by 42
“…of memantine neuroprotection, that has been shown to protect from neurodegeneration through its NMDAR-binding properties (Xia et al. 2010; Chen and Lipton 2006; Volbracht et al. 2006), have been extensively studied, there was no study designed to explore the protective effects of memantine on…”
InfluentialVitamin-D-Free Regimen Intensifies the Spatial Learning Deficit in Alzheimer's Disease
Taghizadeh, M., Djazayery, A., Salami, M., Eshraghian, M. R., & Talaei, S. A. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2010.523132 · Cited by 41
“, 2001) or NMDA receptors (Lipton, 2006), is a necessity for production of experimentally induced synaptic plasticity long-term potentiation, it is a destructive factor for cell protection as well as cognitive performances.”
BackgroundGPCRs Promote the Release of Zinc Ions Mediated by nNOS/NO and the Redox Transducer RGSZ2 Protein
Sánchez‐Blázquez, P., Rodríguez-Muñoz, M., Bailón, C., & Garzón, J. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4517 · Cited by 37
“Typically, NMDAR overactivation at least partially contributes to neurological diseases such as Alzheimer’s and Parkinson’s diseases, multiple sclerosis, and amyotrophic lateral sclerosis (27), as well as mood disorders such as schizophrenia and depression (29, 36).”
Memantine prevents aluminum-induced cognitive deficit in rats
Abdel‐Aal, R. A., Assi, A.-A. A., & Kostandy, B. B. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.06.031 · Cited by 37
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Oh, C.-K., Nakamura, T., Beutler, N., Zhang, X., Piña-Crespo, J., Talantova, M. V., Ghatak, S., Trudler, D., Carnevale, L. N., McKercher, S. R., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01149-6 · Cited by 39
Self-citationSun, Y., Wang, C.-Y., Hsu, M.-F., Juan, S., Chang, C.-Y., Chou, C.-M., Yang, L.-Y., Hung, K.-S., Xu, J., Lee, Y., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2295-10.2010 · Cited by 41
“Neuroprotective strategies for treating CNS disorders have been directed mostly at preserving gray matter or neurons (Lipton, 2006).”
BackgroundNeuroprotective therapies for multiple sclerosis and other demyelinating diseases
Villoslada, P. (2016) · Multiple Sclerosis and Demyelinating Disorders · doi:10.1186/s40893-016-0004-0 · Cited by 40
“Memantine is approved for Alzheimer’s disease and was shown to modulate glutamate excitatory activation [44], but it was found to transiently worsen symptoms in patients with MS, reproducing pseudoexacerbations [45, 46].”
Swerdlow, N. R., Bhakta, S. G., & Light, G. A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.037 · Cited by 37
“It has little impact on basal NMDA transmission; this distinguishes it mechanistically from other NMDA antagonists (Lipton 2006).”
BackgroundNLRP3 inflammasome in NMDA-induced retinal excitotoxicity
Tsoka, P., Barbisan, P. R. T., Kataoka, K., Chen, X. N., Tian, B., Bouzika, P., Miller, J. W., Paschalis, E. I., & Vavvas, D. G. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.01.018 · Cited by 36
“, 2007), clinical trials using memantine (the most common inhibitor of NMDARs) have failed to achieve neuroprotection (Lipton, 2006; Osborne, 2009).”
Saeedi, M., & Mehranfar, F. (2022) · Recent Patents on Biotechnology · doi:10.2174/1872208316666220302115901 · Cited by 41
Han, Z., Yang, J., Jiang, S. X., Hou, S., & Zheng, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064894 · Cited by 36
“Memantine blocks high, pathological levels of agonist more effectively than lower, physiological levels [6,7,12– 14].”
BackgroundCurrent and Emerging Therapies for Alzheimer’s Disease
Nygaard, H. B. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.009 · Cited by 46
Current and emerging molecular targets in glioma
Roesler, R., Brunetto, A. T., Abujamra, A. L., de Farias, C. B., Brunetto, A. L., & Schwartsmann, G. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.167 · Cited by 37
Memantine partly rescues behavioral and cognitive deficits in an animal model of neurodegeneration
Borre, Y. E., Bosman, E., Lemstra, S., Westphal, K. G. C., Olivier, B., & Oosting, R. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.034 · Cited by 38
“First, it may block NMDA receptormediated excitotoxicity (Lipton, 2006), and second, it may prevent microglia activation (Rosi et al., 2006 and Wu et al., 2009).”
InfluentialNovelN-methyl- d -aspartate receptor antagonists: a review of compounds patented since 2006
Koller, M., & Urwyler, S. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.533656 · Cited by 37
“With its modest affinity of about 1 μM, the channel blocker memantine is a good example of a clinically successful drug following this concept [76].”
BackgroundHydroxysafflor Yellow A Protects Neurons From Excitotoxic Death through Inhibition of NMDARs
Wang, X., Ma, Z., Fu, Z., Gao, S., Liu, Y., Jin, Y., Sun, H. Q., Wang, C., Fan, W.-M., Chen, L., et al. (2016) · ASN NEURO · doi:10.1177/1759091416642345 · Cited by 37
“However, subsequent clinical trials involving the therapeutic use of NMDAR antagonists in brain ischemia failed due to the fact that the NMDARs play important roles in maintaining normal synaptic transmission and neuronal growth, as well as regulating neuronal survival and recovery following brain ischemia (Birmingham…”
BackgroundInfluentialTorres, E., Duque, M. D., Vanderlinden, E., Ma, C., Pinto, L. H., Camps, P., Froeyen, M., Vázquez, S., & Naesens, L. M. J. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.06.006 · Cited by 35
“Moreover, Amt and its dimethyl derivative memantine are NMDA receptor antagonists approved for the treatment of Parkinson’s and Alzheimer’s disease, respectively (Lipton, 2006; Hubsher et al., 2012) (Fig.”
BackgroundMagnesium supplementation in the treatment of dementia patients
Öztürk, Ş., & Çilliler, A. E. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.04.047 · Cited by 39
Liu, S., Xu, G., Johnson, K. M., Echetebu, C. O., Ye, Z., Hulsebosch, C. E., & McAdoo, D. J. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.035 · Cited by 40
Oh, Y., Do, H. T. T., Kim, S.-Y., Kim, Y., Chin, Y., & Cho, J. (2020) · Antioxidants · doi:10.3390/antiox10010034 · Cited by 35
“Additionally, overactivation of NMDA receptors accentuates the toxic effects of free radicals, including ROS and nitric oxide, and activates caspases and apoptosis-inducing factors [47].”
BackgroundNew RNA-Based Breakthroughs in Alzheimer’s Disease Diagnosis and Therapeutics
Riscado, M., Baptista, B., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091397 · Cited by 35
Chapter 28 Identification of Novel Pharmacological Targets to Minimize Excitotoxic Retinal Damage
Russo, R., Rotiroti, D., Tassorelli, C., Nucci, C., Bagetta, G., Bucci, M. G., Corasaniti, M. T., & Morrone, L. A. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)85028-9 · Cited by 38
Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid
Tozzi, A., Costa, C., Filippo, M. D., Tantucci, M., Siliquini, S., Belcastro, V., Parnetti, L., Picconi, B., & Calabresi, P. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.008 · Cited by 34
Wild, A. R., Akyol, E., Brothwell, S. L. C., Kimkool, P., Skepper, J. N., Gibb, A. J., & Jones, S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.013 · Cited by 34
“The potent use-dependent channel blocker, MK-801 (MacDonald et al., 1991), is effective in reducing excitotoxicity, most likely due to the slow rate of dissociation from the binding site in the NMDAR channel (reviewed by Lipton, 2006).”
InfluentialKrishna, K. V., Saha, R. N., Singhvi, G., & Dubey, S. K. (2018) · RSC Advances · doi:10.1039/c8ra03379j · Cited by 34
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 37
“A modified version of memantine , namely nitromemantine [81], combined the affinity of E-NMDARs with the introduction of a nitro group acting as a NO/redox modulator.”
Vercelli, A., Biggi, S., Sclip, A., Repetto, I. E., Cimini, S., Falleroni, F., Tomasi, S., Monti, R., Tonna, N., Morelli, F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.226 · Cited by 35
“Alzheimer disease, spinal cord injury, traumatic brain injury, hearing loss, Parkinson’s andHuntington diseases.(1) However,”
BackgroundWang, X., Yu, H., You, J., Wang, C., Feng, C.-M., Liu, Z., Li, Y., Wei, R., Xu, S., Zhao, R., et al. (2018) · Toxicology · doi:10.1016/j.tox.2018.05.013 · Cited by 35
Rivas‐Santisteban, R., Lillo, A., Lillo, J., Rebassa, J. B., Contestí, J. S., Saura, C. A., Franco, R., & Navarro, G. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00920-6 · Cited by 34
Pharmacological Treatment for Neuroinflammation in Stress-Related Disorder
Lee, D.-H., Lee, J., Hong, D.-Y., Lee, E.-C., Park, S.-W., Lee, Y. K., & Oh, J. S. (2022) · Biomedicines · doi:10.3390/biomedicines10102518 · Cited by 34
“They block excess activity while preserving physiological NMDA receptor activity, and only blocks receptor ion channels when the channel is excessively opened [76].”
BackgroundLiu, Z., Yang, S., Jin, X., Zhang, G., Guo, B., Chen, H., Yu, P., Sun, Y., Zhang, Z., & Wang, Y. (2016) · MedChemComm · doi:10.1039/c6md00509h · Cited by 33
Xu, L., Ren, Z., Chow, F. E., Tsai, R., Liu, T., Rizzolio, F., Boffo, S., Xu, Y., Huang, S., Lippa, C. F., et al. (2017) · Neural Plasticity · doi:10.1155/2017/3270725 · Cited by 33
Lobine, D., Sadeer, N., Jugreet, S., Suroowan, S., Keenoo, B. S., Imran, M., Venugopala, K. N., Ibrahim, F. M., Zengin, G., & Mahomoodally, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210412095251 · Cited by 32
“The fast off-rate prevents memantine from building up in NMDAR-operated channels, thereby preventing interference with physiological neurotransmission [86].”
BackgroundIp, F. C. F., Zhao, Y., Chan, K.-W., Cheng, E. Y.-L., Tong, E. P. S., Chandrashekar, O., Fu, G., Zhao, Z., & Ip, N. Y. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1417-1 · Cited by 33
“Many neuroprotective compounds have been demonstrated to be effective in animal models of cerebral ischemia, and some candidates are being actively pursued in clinical trials (e.g. clinical trials with identifiers NCT02315443, NCT02222714, NCT01454154, NCT01221246, NCT01502761, NCT02144584 and NCT02535611), including…”
BackgroundResultInfluentialSong, Z., Yin, F., Xiang, B., Lan, B., & Cheng, S. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/5194016 · Cited by 36
“NMDA subtypes of glutamate receptors are agents that rely on the death of cells dependent onCa [100], which can lead to degenerative disorders due to excessive or inappropriate activity [101].”
BackgroundAducanumab: A new hope in Alzheimer's disease
Ali, R., Gupta, G. D., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100039 · Cited by 37
Luo, J., Li, W., Zhao, Y., Fu, H., Ma, D., Tang, J., Li, Z., Peoples, R. W., Li, F., Wang, Q., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.111286 · Cited by 33
Baudry, M. (2010) · Open Access Bioinformatics · doi:10.2147/oab.s7246 · Cited by 35
“34,35 Usefulness of a detailed model of NMDARs More generally, the detailed kinetic model of NMDARs we have developed could provide a very useful tool to determine the influence of a variety of compounds acting on various elements of the model on NMDAR function and under a variety of experimental…”
The Local Anesthetic Effect of Memantine on Infiltrative Cutaneous Analgesia in the Rat
Chen, Y., Chu, C., Chen, Y.-C., Wang, J., & Hung, C. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3182172a00 · Cited by 31
Rosini, M., Simoni, E., Bartolini, M., Soriano, E., Marco‐Contelles, J., Andrisano, V., Monti, B., Windisch, M., Hutter‐Paier, B., McClymont, D. W., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300263 · Cited by 31
Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery
Bian, Y., Jun, J. J., Cuyler, J., & Xie, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112690 · Cited by 33
Neuroprotection by glucagon: role of gluconeogenesis
Fanne, R. A., Nassar, T., Mazuz, A., Waked, O., Heyman, S. N., Hijazi, N., Goelman, G., & Higazi, A. A. (2010) · Journal of neurosurgery · doi:10.3171/2010.4.jns10263 · Cited by 31
Brittain, M. K., Brustovetsky, T., Brittain, J. M., Khanna, R., Cummins, T., & Brustovetsky, N. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.012 · Cited by 31
“However, strong inhibition of glutamate neurotransmission with highaffinity NMDAR antagonists such as MK801 leads to unacceptable side-effects (Lipton, 2006).”
Štimac, A., Šegota, S., Sikirić, M. D., Ribić, R., Frkanec, L., Svetličić, V., Tomić, S., Vranešić, B., & Frkanec, R. (2012) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2012.04.002 · Cited by 31
Špilovská, K., Korábečný, J., Horova, A., Musílek, K., Nepovimová, E., Drtinová, L., Gažová, Z., Šipošová, K., Doležal, R., Jun, D., et al. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1316-x · Cited by 31
“Memantine (1-amino-3,5-dimethyladamantane) is used as a neuroprotective agent in the treatment of AD with different mechanism of action (NMDA receptor antagonist) (Kotermanski and Johnson, 2009; Lipton, 2006; Schmitt, 2005).”
A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer’s disease
Schmitt, F. A., Ryan, M. A., & Cooper, G. E. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.1.135 · Cited by 31
“, AD) is beyond the scope of this review, other reviews have appeared in the literature regarding glutamate and excitotoxicity [8,9].”
BackgroundMemantine as a neuroprotective agent in ischemic stroke: Preclinical and clinical analysis
Pichardo-Rojas, D., Pichardo-Rojas, P. S., Cornejo‐Bravo, J. M., & Serrano‐Medina, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1096372 · Cited by 34
“Memantine preferentially binds hyperactive NMDA receptors without disrupting the normally functioning NMDA cation channels (Chen and Lipton, 2006).”
BackgroundResultHou, J., Klippel, K., & Bose, P. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl38904 · Cited by 34
“Nitromemantine Memantine derivative targeting extrasynaptic NMDA receptors; includes nitric oxide moiety Enhanced neuroprotection and synaptic preservation in preclinical Alzheimer’s models; reduced excitotoxicity with fewer side effects [82,83].”
Effects of memantine on mitochondrial function
McAllister, J., Ghosh, S., Berry, D., Park, M., Sadeghi, S., Wang, K. X., Parker, W. D., & Swerdlow, R. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.10.019 · Cited by 35
“Memantine is a moderate-affinity NMDA receptor antagonist [7].”
BackgroundMak, S., Li, W., Fu, H., Luo, J., Cui, W., Hu, S., Pang, Y., Carlier, P. R., Tsim, K. W. K., Pi, R., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15379 · Cited by 30
“Memantine, the first and only NMDA receptor antagonist for treating AD, is an example of the PAT properties, meeting the criteria of drugs for various neurodegenerative disorders (Lipton, 2005, 2006).”
BackgroundGluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models
Mahfooz, K., Marco, S., Martínez-Turrillas, R., Raja, M. K., Pérez‐Otaño, I., & Wesseling, J. F. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.04.001 · Cited by 32
Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13
Fan, M., Xu, H., Wang, L., Luo, H., Zhu, X., Cai, P., Wei, L., Lu, L., Cao, Y., Ye, R., et al. (2016) · Scientific Reports · doi:10.1038/srep25971 · Cited by 30
Effgen, G. B., & Morrison, B. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2016.4528 · Cited by 30
Glasgow, N. G., Wilcox, M. R., & Johnson, J. W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.017 · Cited by 30
“Memantine is approved for the treatment of moderate to severe Alzheimer's disease and is clinically well tolerated (Lipton, 2006; Parsons et al., 2007; Parsons and Raymond, 2014).”
Liu, H.-P., Lin, W.-Y., Liu, S.-H., Wang, W.-F., Tsai, C.-H., Wu, B.-T., Wang, C.-K., & Tsai, F.-J. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000254757 · Cited by 29
Ghaffary, S., Ghaeli, P., Talasaz, A. H., Karimi, A., Noroozıan, M., Salehiomran, A., & Jalali, A. (2017) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-017-0190-0 · Cited by 34
“Subsequently, memantine becomes a very effective NMDA receptor blocker under excitotoxic conditions and prolonged activation of NMDA receptors [8].”
Introductory Chapter: GABA/Glutamate Balance: A Key for Normal Brain Functioning
Samardžić, J., Jadzic, D., Henčić, B., Jančić, J., & Štrac, D. Š. (2018) · InTech eBooks · doi:10.5772/intechopen.74023 · Cited by 34
Guo, Y., Wu, F., & Wang, E. (2015) · Europe PMC (PubMed Central) · Cited by 29
The Central Effects of Androgenic-anabolic Steroid Use
Mędraś, M., Brona, A., & Jóźków, P. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000395 · Cited by 29
Liu, W., Xu, Z., Yang, T., Deng, Y. L., Xu, B., Feng, S., & Li, Y.-K. (2014) · Free Radical Research · doi:10.3109/10715762.2014.916039 · Cited by 30
Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists
Utech, T., Köhler, J., & Wünsch, B. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.070 · Cited by 28
Ryu, I.-H., Lee, K., & Do, S.-I. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.02.003 · Cited by 28
Evidence of Presynaptic Localization and Function of the c-Jun N-Terminal Kinase
Biggi, S., Buccarello, L., Sclip, A., Lippiello, P., Tonna, N., Rumio, C., Marino, D. D., Miniaci, M. C., & Borsello, T. (2017) · Neural Plasticity · doi:10.1155/2017/6468356 · Cited by 28
“In fact, JNK is rapidly activated after glutamate receptors stimulation [59], and in addition plays a key role in NMDA-induced neuronal-death (excitotoxicity; see [10, 60, 61]).”
BackgroundA short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 29
“The only other approved symptomatic treatment for AD is memantine, which is a non‐competitive NMDA glutamate receptor blocker, although its mechanism of action was only discovered during its clinical development, which was driven by empirical observation of symptomatic benefit (Lipton, 2006; McShane, Areosa Sastre, &…”
BackgroundEstablishment of an adult zebrafish model of retinal neurodegeneration induced by NMDA
Luo, Z., Wang, H.-T., Wang, N., Sheng, W., Jin, M., Lu, Y., Bai, Y.-J., Zou, S., Pang, Y., Xu, H. A., et al. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.08.04 · Cited by 29
Motawaj, M., Burban, A., Davenas, E., & Arrang, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174458 · Cited by 28
“…contrast to other NMDAR antagonists, memantine provides neuroprotection while displaying minimal adverse effects, because of its moderate affinity, noncompetitive antagonism, strong voltage dependence, and fast kinetics at NMDARs (Johnson and Kotermanski, 2006; Lipton, 2006; Parsons et al., 2007).”
BackgroundInfluentialGilling, K. E., Jatzke, C., & Parsons, C. G. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.022 · Cited by 30
“The primary aim of this study was to challenge the hypothesis that memantine antagonizes NMDA receptor-mediated currents with greater potency when this agonist is present at higher concentrations e.g. (Chen et al., 1992; Lipton, 2004, 2006, 2007).”
BackgroundResultInfluential
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.